UIM3:F:F-UBS ETF SICAV - FTSE 100 UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 89.56

Change

+0.07 (+0.08)%

Market Cap

USD 0.06B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-11.04 (-2.21%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.17 (+0.35%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+1.08 (+2.09%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.06 (+0.44%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

+0.02 (+0.26%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

-0.03 (-0.04%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.35 (+0.63%)

USD 45.80B
0ZC:F Zscaler Inc

-10.24 (-5.72%)

USD 37.92B
BSND:F Danone SA

+0.10 (+0.70%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-2.28 (-1.95%)

USD 24.77B

ETFs Containing UIM3:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.21% 64% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.21% 64% D 65% D
Trailing 12 Months  
Capital Gain 3.80% 75% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.80% 72% C 58% F
Trailing 5 Years  
Capital Gain 44.24% 53% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.24% 53% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain 8.74% 65% D 62% D
Dividend Return 8.74% 62% D 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.17% 71% C- 93% A
Risk Adjusted Return 95.40% 87% B+ 91% A-
Market Capitalization 0.06B 25% F 26% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.